To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00372294

Enrollment

Unknown

Registered

2006-09-06

Start date

2005-07-31

Completion date

2008-11-30

Last updated

2008-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chorioretinitis

Keywords

Toxoplasmosis, Chorioretinitis, Intravitreal Clindamycin, Dexamethasone in chorioretinitis, Toxoplasmic

Brief summary

Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The goal of treatment is arresting multiplication of the parasite in its inflammatory active phase. In this study the investigators try to compare the efficacy of the classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon) with intravitreal Clindamycin & Dexamethasone.

Interventions

DRUGpyrimethamine-sulfadiazine + prednisolone

Administration of pyrimethamine-sulfadiazine + prednisolone

DRUGClindamycin+Dexamethasone

Intravitreal injection of Clindamycin+Dexamethasone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with Toxoplasmic chorioretinitis * Location of the lesion within zone I of the retina or a lesion greater than 2DD with 3+-4+ vitreous inflammation in zone II or III * No allergic history to the used drugs * No any other diseases

Exclusion criteria

* Any allergic reaction to the used medications * One eyed patients * Partially treated patients

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026